If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2021-09-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED AUGUST 31, 2021
2021-08-30
VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
2021-08-30
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
2021-08-26
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FIRST PERSON DOSED IN GLOBAL PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY IN CHINA FOR METASTATIC UROTHELIAL CANCER
2021-08-16
DATE OF BOARD MEETING
2021-08-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED JULY 31, 2021
2021-08-05
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NMPA FOR PHASE 3 TRIAL OF XERAVATM FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
2021-07-29
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON TAIWAN FDA GRANTING PEDIATRIC AND RARE SEVERE DISEASE PRIORITY REVIEW DESIGNATION FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
2021-07-20
VOLUNTARY ANNOUNCEMENT STRATEGIC COLLABORATION WITH MEDITRUST HEALTH CO., LTD TO DEVELOP NOVEL PAYMENT SOLUTIONS FOR PATIENTS IN CHINA
2021-07-15
1) GRANT OF SHARE OPTIONS, (2) GRANT OF SHARE AWARDS, (3) NON-EXEMPT CONNECTED TRANSACTION -- PROPOSED GRANT OF SHARE AWARDS TO CONNECTED PERSONS, AND (4) PROPOSED FUTURE AWARD GRANTS
